Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:ADC |
Matrix-M
|
| gptkbp:antiSubmarineWarfare |
considerations in distribution
|
| gptkbp:clinicalTrials |
gptkb:Novavax
multiple countries Phase 3 published in medical journals |
| gptkbp:communityImpact |
measures effectiveness in real-world settings
|
| gptkbp:dataUsage |
collected from clinical trials
|
| gptkbp:developedBy |
gptkb:Novavax
|
| gptkbp:diseaseResistance |
public awareness campaigns
logistical issues ongoing assessments importance of transparency expedited review process influences vaccination strategies |
| gptkbp:dosageForm |
21 days
|
| gptkbp:evaluates |
approximately 90%
|
| gptkbp:expansion |
recommended after initial series
|
| gptkbp:firstHeld |
two doses
|
| gptkbp:foughtAgainst |
contributes to herd immunity
|
| gptkbp:hasCollaborationsWith |
with international organizations
|
| gptkbp:healthcare |
contributes to pandemic response
|
| gptkbp:historicalResearch |
with academic institutions
|
| https://www.w3.org/2000/01/rdf-schema#label |
NVX-CoV2373
|
| gptkbp:lengthOverall |
assess durability of immunity
|
| gptkbp:marketSegment |
available in some countries
|
| gptkbp:muzzleVelocity |
aims for equitable distribution
|
| gptkbp:notable_player |
global supply chain
government and private sectors ongoing studies requires refrigeration post-marketing surveillance neutralizing antibodies requires trained personnel involves local stakeholders against variants reduces severe disease subunit vaccine against hospitalization collaborations with other companies advancements in vaccine technology recombinant technology by various health authorities |
| gptkbp:providesAccessTo |
supports regulatory submissions
|
| gptkbp:regulatoryCompliance |
Emergency Use Authorization
|
| gptkbp:route |
intramuscular
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
headache muscle pain fever injection site reactions |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:takesPlaceIn |
involves diverse populations
|
| gptkbp:targets |
gptkb:COVID-19
adults |
| gptkbp:team |
recommended for use
|
| gptkbp:triggerType |
induces immune response
|
| gptkbp:type |
protein subunit vaccine
|